Arcutis Biotherapeutics (AQRT) PT Raised to $35 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Guggenheim analyst Seamus Fernandez raised the price target on Arcutis Biotherapeutics (: AQRT) to $35.00 (from $34.00) while maintaining a Buy rating.
You May Also Be Interested In
- AMD (AMD) PT Raised to $600 at DA Davidson
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
- Red Rock Resorts (RRR) PT Lowered to $60 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
